Tenofovir Alafenamide Fumarate is named as a drug or biological intervention in 3 clinical trials in our China and India trial registers, 1 of which is recruiting. Lead sponsors include Institute of Liver and Biliary Sciences, India (1), Xiamen Amoytop Biotech Co., Ltd. (1) and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1). Registered phases: Not applicable and Phase 3. Conditions studied include Chronic Hepatitis B; Non-cirrhotic, Chronic Hepatitis B.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05195450 | TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load. (ClinicalTrials.gov ↗) Non-cirrhotic, Chronic Hepatitis B |
Not applicable | Recruiting |
| NCT07797231 | Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response (ClinicalTrials.gov ↗) Chronic Hepatitis B |
Phase 3 | Not yet open |
| NCT06707922 | A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (ClinicalTrials.gov ↗) Chronic Hepatitis B |
Not applicable | By invitation |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Chronic Hepatitis B | 2 |
| Non-cirrhotic, Chronic Hepatitis B | 1 |
| Lead sponsor | Trials |
|---|---|
| Institute of Liver and Biliary Sciences, India | 1 |
| Xiamen Amoytop Biotech Co., Ltd. | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| Register | Tenofovir Alafenamide Fumarate trials |
|---|---|
| Clinical trials in China | 2 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tenofovir Alafenamide Fumarate works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tenofovir Alafenamide Fumarate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.